Chronic myelogenous leukemia: mechanisms underlying disease progression
Open accessThe DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
A minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
PI3K: Downstream AKTion Blocks Apoptosis
Franke, T. F., Kaplan, D. R., & Cantley, L. C. (1997) · Cell · doi:10.1016/s0092-8674(00)81883-8 · Cited by 1,668
A novel form of Epstein-Barr virus latency in normal B cells in vivo
Miyashita, E. M., Yang, B., Lam, K. M. C., Crawford, D. H., & Thorley-Lawson, D. A. (1995) · Cell · doi:10.1016/0092-8674(95)90513-8 · Cited by 1,593
The Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene
Tybulewicz, V. L. J., Crawford, C. E., Jackson, P. K., Bronson, R. T., & Mulligan, R. C. (1991) · Cell · doi:10.1016/0092-8674(91)90011-m · Cited by 1,281
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., & Weinberg, R. A. (1993) · Nature · doi:10.1038/363045a0 · Cited by 1,215
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid Gene
Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A.-M., Witte, O. N., & Baltimore, D. (1986) · Science · doi:10.1126/science.3460176 · Cited by 806
Pear, W. S., Miller, J. P., Xu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., Bronson, R., Aster, J. C., Scott, M. L., et al. (1998) · Blood · doi:10.1182/blood.v92.10.3780 · Cited by 755
Cell Surface Trafficking of Fas: A Rapid Mechanism of p53-Mediated Apoptosis
Bennett, M., Macdonald, K., Chan, S.-W., Luzio, J. P., Simari, R., & Weissberg, P. (1998) · Science · doi:10.1126/science.282.5387.290 · Cited by 754
Bcl-2 Gene Family and the Regulation of Programmed Cell Death
Yin, X.-M., Oltvai, Z. N., Veis-Novack, D. J., Linette, G. P., & Korsmeyer, S. J. (1994) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1994.059.01.043 · Cited by 723
Acute leukaemia in bcr/abl transgenic mice
Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P. K., & Groffen, J. (1990) · Nature · doi:10.1038/344251a0 · Cited by 672
Mahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 584
Interaction of c-Abl and p73α and their collaboration to induce apoptosis
Agami, R., Blandino, G., Oren, M., & Shaul, Y. (1999) · Nature · doi:10.1038/21697 · Cited by 546
Baskaran, R., Wood, L. D., Whitaker, L. L., Canman, C. E., Morgan, S. E., Xu, Y., Barlow, C., Baltimore, D., Wynshaw-Boris, A., Kastan, M. B., et al. (1997) · Nature · doi:10.1038/387516a0 · Cited by 539
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Kelliher, M. A., McLaughlin, J., Witte, O. N., & Rosenberg, N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6649 · Cited by 514
Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
Bedi, A., Zehnbauer, B., Barber, J., Sharkis, S., & Jones, R. (1994) · Blood · doi:10.1182/blood.v83.8.2038.2038 · Cited by 508
Li, S., Ilaria, R. L., Million, R. P., Daley, G. Q., & Van Etten, R. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1399 · Cited by 501
Ilaria, R. L., & Van Etten, R. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31704 · Cited by 488
Carlesso, N., Frank, D. A., & Griffin, J. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.811 · Cited by 483
McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K., Green, D., & Cotter, T. (1994) · Blood · doi:10.1182/blood.v83.5.1179.1179 · Cited by 472
Silver, R. T., Woolf, S. H., Hehlmann, R., Appelbaum, F. R., Anderson, J., Bennett, C., Goldman, J. M., Guilhot, F., Kantarjian, H. M., Lichtin, A. E., et al. (1999) · PubMed · Cited by 463
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Puil, L., Liu, J., Gish, G., Mbamalu, G., Bowtell, D., Pelicci, P. G., Arlinghaus, R., & Pawson, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06319.x · Cited by 438
Gordon, M. Y., Dowding, C. R., Riley, G. P., Goldman, J. M., & Greaves, M. F. (1987) · Nature · doi:10.1038/328342a0 · Cited by 436
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., & Sawyers, C. L. (1996) · PubMed · Cited by 434
Drexler, H. (1998) · Leukemia · doi:10.1038/sj.leu.2401043 · Cited by 426
McWhirter, J. R., Galasso, D. L., & Wang, J. Y. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.12.7587 · Cited by 420
Kantarjian, H. M., Smith, T. L., O'Brien, S., Beran, M., Pierce, S., Talpaz, M., & Service*, A. T. L. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-4-199502150-00003 · Cited by 417
Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M., Wen, S., Zon, G., Gewirtz, A., Perussia, B., & Calabretta, B. (1995) · Blood · doi:10.1182/blood.v86.2.726.bloodjournal862726 · Cited by 404
Weisberg, E., & Griffin, J. D. (2000) · Blood · doi:10.1182/blood.v95.11.3498 · Cited by 401
Dominant negative MYC blocks transformation by ABL oncogenes
Sawyers, C. L., Callahan, W., & Witte, O. N. (1992) · Cell · doi:10.1016/0092-8674(92)90241-4 · Cited by 397
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Raitano, A. B., Halpern, J. R., Hambuch, T. M., & Sawyers, C. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11746 · Cited by 394
A requirement for NF-kappa B activation in Bcr-Abl-mediated transformation
Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M., & Baldwin Jr., A. S. (1998) · Genes & Development · doi:10.1101/gad.12.7.968 · Cited by 392
Muller, A. J., Young, J. C., Pendergast, A. M., Pondel, M., Landau, N. R., Littman, D. R., & Witte, O. N. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.4.1785 · Cited by 377
McLaughlin, J., Chianese, E., & Witte, O. N. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.18.6558 · Cited by 367
Horita, M., Andreu, E. J., Benito, A., Arbona, C., Sanz, C., Benet, I., Prosper, F., & Fernandez-Luna, J. L. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.977 · Cited by 366
Carpino, N., Wisniewski, D., Strife, A., Marshak, D., Kobayashi, R., Stillman, B., & Clarkson, B. (1997) · Cell · doi:10.1016/s0092-8674(00)81840-1 · Cited by 362
Bedi, A., Barber, J., Bedi, G., el-Deiry, W., Sidransky, D., Vala, M., Akhtar, A., Hilton, J., & Jones, R. (1995) · Blood · doi:10.1182/blood.v86.3.1148.1148 · Cited by 349
Elefanty, A. G., Hariharan, I. K., & Cory, S. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08212.x · Cited by 344
Vigneri, P., & Wang, J. Y. J. (2001) · Nature Medicine · doi:10.1038/84683 · Cited by 331
Mitani, K., Ogawa, S., Tanaka, T., Miyoshi, H., Kurokawa, M., Mano, H., Yazaki, Y., Ohki, M., & Hirai, H. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06288.x · Cited by 325
Gambacorti-Passerini, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1641 · Cited by 320
McWhirter, J. R., & Wang, J. Y. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05797.x · Cited by 317
Amarante-Mendes, G. P., Naekyung Kim, C., Liu, L., Huang, Y., Perkins, C. L., Green, D. R., & Bhalla, K. (1998) · Blood · doi:10.1182/blood.v91.5.1700 · Cited by 316
Sinclair, P. B., Nacheva, E. P., Leversha, M., Telford, N., Chang, J., Reid, A., Bench, A., Champion, K., Huntly, B., & Green, A. R. (2000) · Blood · doi:10.1182/blood.v95.3.738.003k21_738_743 · Cited by 310
Kinoshita, T., Yokota, T., Arai, K., & Miyajima, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07000.x · Cited by 298
Ahuja, H., Bar-Eli, M., Advani, S. H., Benchimol, S., & Cline, M. J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6783 · Cited by 284
Regulation of cell death by the Abl tyrosine kinase
Wang, J. Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203878 · Cited by 278
Chronic myelogenous leukemia in blast crisis
Kantarjian, H. M., Keating, M. J., Talpaz, M., Walters, R. S., Smith, T. L., Cork, A., McCredie, K. B., & Freireich, E. J. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90754-6 · Cited by 277
Van Etten, R. A. (1994) · The Journal of Cell Biology · doi:10.1083/jcb.124.3.325 · Cited by 268
Cortez, D., Kadlec, L., & Pendergast, A. M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5531 · Cited by 267
Molecular Cloning Of Human Paxillin, a Focal Adhesion Protein Phosphorylated by P210BCR/ABL
Salgia, R., Li, J.-L., Lo, S. H., Brunkhorst, B., Kansas, G. S., Sobhany, E. S., Sun, Y., Pisick, E., Hallek, M., Ernst, T., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5039 · Cited by 267
Sawyers, C. L., McLaughlin, J., & Witte, O. N. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.307 · Cited by 253
Bcr/Abl activates transcription of theBcl-X gene through STAT5
Gesbert, F., & Griffin, J. D. (2000) · Blood · doi:10.1182/blood.v96.6.2269 · Cited by 253
Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene
Goga, A., McLaughlin, J., Afar, D. E. H., Saffran, D. C., & Witte, O. N. (1995) · Cell · doi:10.1016/0092-8674(95)90277-5 · Cited by 248
McGlave, P. B., Shu, X. O., Wen, W., Anasetti, C., Nademanee, A., Champlin, R., Antin, J. H., Kernan, N. A., King, R., & Weisdorf, D. J. (2000) · Blood · doi:10.1182/blood.v95.7.2219 · Cited by 235
Association of the Protein Kinases c-Bcr and Bcr-Abl with Proteins of the 14-3-3 Family
Reuther, G. W., Fu, H., Cripe, L. D., Collier, R. J., & Pendergast, A. M. (1994) · Science · doi:10.1126/science.7939633 · Cited by 229
BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice
Voncken, J., Kaartinen, V, Pattengale, P., Germeraad, W., Groffen, J., & Heisterkamp, N. (1995) · Blood · doi:10.1182/blood.v86.12.4603.bloodjournal86124603 · Cited by 216
Cortez, D., Reuther, G., & Pendergast, A. M. (1997) · Oncogene · doi:10.1038/sj.onc.1201400 · Cited by 216
Wen, S. T., Jackson, P. K., & Van Etten, R. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00503.x · Cited by 200
Sill, H., Goldman, J., & Cross, N. (1995) · Blood · doi:10.1182/blood.v85.8.2013.bloodjournal8582013 · Cited by 197
Increased neutrophil respiratory burst in bcr-null mutants
Voncken, J. W., Schaick, H. V., Kaartinen, V., Deemer, K., Coates, T., Landing, B., Pattengale, P., Dorseuil, O., Bokoch, G. M., Groffen, J., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90350-x · Cited by 197
Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.
Sánchez-García, I., & Grütz, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5287 · Cited by 192
Wetzler, M., Talpaz, M., Van Etten, R. A., Hirsh-Ginsberg, C., Beran, M., & Kurzrock, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116786 · Cited by 188
Differential Complementation of Bcr-Abl Point Mutants with c-Myc
Afar, D. E. H., Goga, A., McLaughlin, J., Witte, O. N., & Sawyers, C. L. (1994) · Science · doi:10.1126/science.8153630 · Cited by 184
The Cytogenetic Scenario of Chronic Myeloid Leukemia
Mitelman, F. (1993) · Leukemia & Lymphoma · doi:10.3109/10428199309047856 · Cited by 184
STAT5-Dependent CyclinD1 and Bcl-xL Expression in Bcr-Abl-Transformed Cells
de Groot, R. P., Raaijmakers, J. A. M., Lammers, J. J., & Koenderman, L. (2000) · Molecular Cell Biology Research Communications · doi:10.1006/mcbr.2000.0231 · Cited by 176
Abl tyrosine kinase in signal transduction and cell-cycle regulation
Wang, J. Y. J. (1993) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(05)80338-7 · Cited by 174
Wickremasinghe, R. G., & Hoffbrand, A. V. (1999) · Blood · doi:10.1182/blood.v93.11.3587 · Cited by 172
BCR-ABL down-regulates the DNA repair protein DNA-PKcs
Deutsch, E., Dugray, A., AbdulKarim, B., Marangoni, E., Maggiorella, L., Vaganay, S., M'Kacher, R., Rasy, S. D., Eschwege, F., Vainchenker, W., et al. (2001) · Blood · doi:10.1182/blood.v97.7.2084 · Cited by 166
Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells
Mandanas, R., Leibowitz, D., Gharehbaghi, K., Tauchi, T., Burgess, G., Miyazawa, K., Jayaram, H., & Boswell, H. (1993) · Blood · doi:10.1182/blood.v82.6.1838.1838 · Cited by 165
The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
Ahuja, H., Bar-Eli, M., Arlin, Z., Advani, S., Allen, S. L., Goldman, J., Snyder, D., Foti, A., & Cline, M. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115234 · Cited by 161
Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family
Hoekstra, M. F. (1997) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(97)80125-6 · Cited by 161
Gaiger, A., Henn, T., Horth, E., Geissler, K., Mitterbauer, G., Maier-Dobersberger, T., Greinix, H., Mannhalter, C., Haas, O., & Lechner, K. (1995) · Blood · doi:10.1182/blood.v86.6.2371.bloodjournal8662371 · Cited by 160
Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro
Gishizky, M., & Witte, O. (1992) · Science · doi:10.1126/science.1375394 · Cited by 158
Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.
Gishizky, M. L., Johnson-White, J., & Witte, O. N. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3755 · Cited by 149
BCR/ABL induces multiple abnormalities of cytoskeletal function
Salgia, R., Li, J. L., Ewaniuk, D. S., Pear, W., Pisick, E., Burky, S. A., Ernst, T., Sattler, M., Chen, L. B., & Griffin, J. D. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119520 · Cited by 147
Pierson, B., & Miller, J. (1996) · Blood · doi:10.1182/blood.v88.6.2279.bloodjournal8862279 · Cited by 141
Mashal, R. D., Shtalrid, M., Talpaz, M., Kantarjian, H., Smith, L., Beran, M., Cork, A., Trujillo, J., Gutterman, J. U., & Deisseroth, A. (1990) · Blood · doi:10.1182/blood.v75.1.180.180 · Cited by 141
The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway.
Cortez, D., Stoica, G., Pierce, J. H., & Pendergast, A. M. (1996) · PubMed · Cited by 138
Wada, C., Shionoya, S., Fujino, Y., Tokuhiro, H., Akahoshi, T., Uchida, T., & Ohtani, H. (1994) · Blood · doi:10.1182/blood.v83.12.3449.3449 · Cited by 137
The control of hematopoiesis and leukemia: from basic biology to the clinic.
Sachs, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4742 · Cited by 135
Frank, D. A., & Varticovski, L. (1996) · PubMed · Cited by 133
Sirard, C., Laneuville, P., & Dick, J. (1994) · Blood · doi:10.1182/blood.v83.6.1575.1575 · Cited by 132
Honda, H., Oda, H., Suzuki, T., Takahashi, T., Witte, O. N., Ozawa, K., Ishikawa, T., Yazaki, Y., & Hirai, H. (1998) · Blood · doi:10.1182/blood.v91.6.2067 · Cited by 132
Tauchi, T., Boswell, H. S., Leibowitz, D. S., & Broxmeyer, H. E. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.1.167 · Cited by 129
Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest
Wu, G. S., Burns, T. F., McDonald, E. R., Meng, R. D., Kao, G. D., Muschel, R. J., Yen, T. J., & El‐Deiry, W. S. (1999) · Oncogene · doi:10.1038/sj.onc.1203025 · Cited by 127
Integrins Regulate the Association and Phosphorylation of Paxillin by c-Abl
Lewis, J. M., & Schwartz, M. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14225 · Cited by 127
Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia
Ahuja, H., Jat, P., Foti, A., Bar‐Eli, M., & Cline, M. (1991) · Blood · doi:10.1182/blood.v78.12.3259.3259 · Cited by 126
Pendergast, A. M., Gishizky, M. L., Havlik, M. H., & Witte, O. N. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.3.1728-1736.1993 · Cited by 122
Nakayama, H., Ishimaru, F., Avitahl, N., Sezaki, N., Fujii, N., Nakase, K., Ninomiya, Y., Harashima, A., Minowada, J., Tsuchiyama, J., et al. (1999) · PubMed · Cited by 118
Cambier, N., Chopra, R., Strasser, A., Metcalf, D., & Elefanty, A. G. (1998) · Oncogene · doi:10.1038/sj.onc.1201490 · Cited by 110
Zion, M., Ben-Yehuda, D., Avraham, A., Cohen, O., Wetzler, M., Melloul, D., & Ben-Neriah, Y. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10722 · Cited by 103
Honda, H., Ushijima, T., Wakazono, K., Oda, H., Tanaka, Y., Aizawa, S., Ishikawa, T., Yazaki, Y., & Hirai, H. (2000) · Blood · doi:10.1182/blood.v95.4.1144.004k04_1144_1150 · Cited by 101
Shtalrid, M., Talpaz, M., Kurzrock, R., Kantarjian, H., Trujillo, J. M., Gutterman, J. U., Yoffe, G., & Blick, M. B. (1988) · Blood · doi:10.1182/blood.v72.2.485.485 · Cited by 98
Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Gotoh, A., Miyazawa, K., Ohyashiki, K., Tauchi, T., Boswell, H. S., Broxmeyer, H. E., & Toyama, K. (1995) · PubMed · Cited by 95
BCR-ABL Delays Apoptosis Upstream of Procaspase-3 Activation
Dubrez, L., Eymin, B., Sordet, O., Droin, N. M., Turhan, A. G., & Solary, É. (1998) · Blood · doi:10.1182/blood.v91.7.2415 · Cited by 94
Blastic transformation of p53-deficient bone marrow cells by p210 bcr/abl tyrosine kinase
Skórski, T., Nieborowska-Skorska, M., Wlodarski, P. K., Perrotti, D., Martinez, R., Wasik, M. A., & Calabretta, B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13137 · Cited by 90
ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block.
Nishii, K., Kabarowski, J. H. S., Gibbons, D. L., Griffiths, S. D., Titley, I., Wiedemann, L. M., & Greaves, M. F. (1996) · PubMed · Cited by 85
Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras
Sánchez-Garcı́a, I., & Martı́n-Zanca, D. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0779 · Cited by 84
BIOLOGY OF CHRONIC MYELOGENOUS LEUKEMIA
Verfaillie, C. M. (1998) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70495-0 · Cited by 81 · cited 1×
“Chronic myelogenous leukemia (CML), characterized by the BCR-ABL gene rearrangement, has been extensively studied. Significant progress has been made in the area of BCR-ABLmediated intracellular signaling, which has led to a better understanding of BCR-ABL-mediated clinical features in chronic phase CML. Disease progr…”
BackgroundSelf-citationFrequent and extensive deletion during the 9,22 translocation in CML
Popenoe, D., Schaefer-Rego, K. E., Mears, J., Bank, A., & Leibowitz, D. S. (1986) · Blood · doi:10.1182/blood.v68.5.1123.1123 · Cited by 81
Amos, T. A. S., Lewis, J. L., Grand, F. H., Gooding, R. P., Goldman, J. M., & Gordon, M. Y. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05308.x · Cited by 79
Zipfel, P. A., Grove, M., Blackburn, K., Fujimoto, M., Tedder, T. F., & Pendergast, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6872 · Cited by 76
Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia.
Ogawa, S., Kurokawa, M., Tanaka, T., Tanaka, K., Hangaishi, A., Mitani, K., Kamada, N., Yazaki, Y., & Hirai, H. (1996) · PubMed · Cited by 74
Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.
Majlis, A., Smith, T. L., Talpaz, M., O'Brien, S., Rios, M. B., & Kantarjian, H. M. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.196 · Cited by 74
Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia
LeMaistre, A., Lee, M., Talpaz, M., Kantarjian, H., Freireich, E., Deisseroth, A., Trujillo, J., & Stass, S. A. (1989) · Blood · doi:10.1182/blood.v73.4.889.889 · Cited by 69
Chronic myeloid leukemia from basics to bedside
Thijsen, S. F. T., Schuurhuis, G. J., Oostveen, J. W. V., & Ossenkoppele, G. J. (1999) · Leukemia · doi:10.1038/sj.leu.2401565 · Cited by 68
Bhatia, R., & Verfaillie, C. M. (1998) · Blood · doi:10.1182/blood.v91.9.3414 · Cited by 68
Self-citationFoti, A., Ahuja, H., Allen, S. L., Koduru, P. R. K., Schuster, M., Schulman, P., Bar‐Eli, M., & Cline, M. (1991) · Blood · doi:10.1182/blood.v77.11.2441.2441 · Cited by 65
Methylation of the ABL1 Promoter in Chronic Myelogenous Leukemia: Lack of Prognostic Significance
Issa, J. J., Kantarjian, H. M., MOHAN, A. L., O'Brien, S. M., Cortes, J. E., Pierce, S. A., & Talpaz, M. (1999) · Blood · doi:10.1182/blood.v93.6.2075.406k29_2075_2080 · Cited by 64
Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells.
Harrison-Findik, D. D., Susa, M., & Varticovski, L. (1995) · PubMed · Cited by 63
Serra, A., Gottardi, E. M., Ragione, F. D., Saglio, G. N., & Iolascon, A. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05358.x · Cited by 62
c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells
Ceballos, E., Delgado, M. D., Gutierrez, P., Richard, C., Müller, D., Eilers, M., Ehinger, M., Gullberg, U., & León, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203541 · Cited by 61
Skórski, T., Nieborowska-Skorska, M., Wlodarski, P. K., Zon, G., Iozzo, R. V., & Calabretta, B. (1996) · Blood · doi:10.1182/blood.v88.3.1005.1005 · Cited by 60
Handa, H., Hegde, U. P., Kotelnikov, V. M., Mundle, S. D., Dong, L., Burke, P., Rose, S. H., Gaskin, F., Raza, A., & Preisler, H. D. (1997) · Leukemia Research · doi:10.1016/s0145-2126(97)00006-4 · Cited by 53
Groffen, J., & Heisterkamp, N. (1987) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(87)80035-5 · Cited by 53
Stuppia, L., Calabrese, G., Peila, R., Guanciali‐Franchi, P., Morizio, E., Spadano, A., & Palka, G. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00413-x · Cited by 49
Structurally altered Evi-1 protein generated in the 3q21q26 syndrome.
Ogawa, S., Kurokawa, M., Tanaka, T. U., Mitani, K., Inazawa, J., Hangaishi, A., Tanaka, K., Matsuo, Y., Minowada, J., Tsubota, T., et al. (1996) · PubMed · Cited by 48
Albrecht, T., Schwab, R., Henkes, M., Peschel, C., Huber, C., & Aulitzky, W. E. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.d01-1934.x · Cited by 45
Molecular characteristics of chronic myelogenous leukemia in blast crisis
Blick, M. B., Romero, P., Talpaz, M., Kurzrock, R., Shtalrid, M., Andersson, B. S., Trujillo, J. M., Beran, M., & Gutterman, J. U. (1987) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(87)90018-5 · Cited by 44
Foti, A., Bar‐Eli, M., Ahuja, H. G., & Cline, M. J. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb07849.x · Cited by 39
Molecular Follow-Up of Disease Progression and Interferon Therapy in Chronic Myelocytic Leukemia
Ben‐Yehuda, D., Krichevsky, S., Rachmilewitz, E. A., Avraham, A., Palumbo, G. A., Frassoni, F., Sahar, D., Rosenbaum, H., Paltiel, O., Zion, M., et al. (1997) · Blood · doi:10.1182/blood.v90.12.4918 · Cited by 39
p53 Mutations, Methylation and Genomic Instability in the Progression of Chronic Myeloid Leukaemia
Guinn, B., & Mills, K. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709051771 · Cited by 38
Gordon, M. Y., Dazzi, F., Marley, S., Lewis, J., Nguyen, D., Grand, F. H., Davidson, R., & Goldman, J. M. (1999) · Leukemia · doi:10.1038/sj.leu.2401281 · Cited by 36
BCR-ABL: An Anti-Apoptosis Gene in Chronic Myelogenous Leukemia
Cotter, T. G. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509059612 · Cited by 33
Role of p53 in leukemogenesis of chronic myeloid leukemia
Lanza, F., & Bi, S. (1995) · Stem Cells · doi:10.1002/stem.5530130416 · Cited by 32
Functional role for the c-Abl protein tyrosine kinase in the cellular response to genotoxic stress
Kharbanda, S. M., Yuan, Z.-M., Weichselbaum, R. R., & Kufe, D. W. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00020-6 · Cited by 31
Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia
Grießhammer, M., Heinze, B., Bangerter, M., Heimpel, H., & Fliedner, T. M. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050173 · Cited by 30
Gambacorti-Passerini, C. B., Barni, R., Marchesi, E., Verga, M., Rossi, F., Rossi, F., Pioltelli, P. E., Pogliani, E., & Corneo, G. M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02653.x · Cited by 26
p16ink4aGene and Hematological Malignancies
Quesnel, B., Preudhomme, C., & Fenaux, P. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609051724 · Cited by 25
The Role of Autologous Natural Killer Cells in Chronic Myelogenous Leukemia
Pierson, B. A., & Miller, J. S. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709058306 · Cited by 24
Initiation of Deregulated Growth of Multipotent Progenitor Cells by bcr-abl in Vitro
Gishizky, M. L., & Witte, O. N. (1992) · Science · doi:10.1126/science.256.5058.836 · Cited by 23
Absence of microsatellite instability during the progression of chronic myelocytic leukemia
Mori, N., Takeuchi, S., Tasaka, T., Lee, S. W., Spira, S., Ben‐Yehuda, D., Mizoguchi, H., Schiller, G. J., & Koeffler, H. (1997) · Leukemia · doi:10.1038/sj.leu.2400524 · Cited by 20
The Role of FAS-Mediated Apoptosis in Chronic Myelogenous Leukemia
Selleri, C., & Maciejewski, J. P. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009089429 · Cited by 13
RELATED DONOR BONE MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA
Passweg, J. R., Rowlings, P. A., & Horowitz, M. M. (1998) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70497-4 · Cited by 11
Cited by
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
The biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
Gene expression changes associated with progression and response in chronic myeloid leukemia
Radich, J. P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., Sawyers, C., Shah, N., Stock, W., Willman, C. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510423103 · Cited by 583
Nowicki, M. O., Falinski, R., Koptyra, M., Slupianek, A., Stoklosa, T., Gloc, E., Nieborowska-Skorska, M., Blasiak, J., & Skorski, T. (2004) · Blood · doi:10.1182/blood-2004-05-1941 · Cited by 278
Metadata
- Authors
- Shet, A., Jahagirdar, B., & Verfaillie, C.
- Venue
- Leukemia
- Published
- 2002-07-31
- Volume
- 16
- Issue
- 8
- Pages
- 1402-1411
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2051593267
- Cited by
- 162
- References
- 143
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.